Matthew Meyerson

USPTO Granted Patents = 31 (Patent Applications = 19)

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 14 (Patent Applications = 16)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 457(Granted Patents)

Location History:

Concord, MA (US) (2006 - 2024)
Boston, MA (US) (2019 - 2024)

Company Filing History:

31 out of 1,206

Dana-farber-cancer Institute Inc.

patents

15 out of 443

The Broad Institute, Inc.

patents

9 out of 2,882

The General Hospital Corporation

patents

4. 8 out of 378

Bayer Pharma Aktiengesellschaft

patents

5. 6 out of 12,157

Bayer Aktiengesellschaft

patents

6. 1 out of 1,370

The Brigham and Women's Hospital, Inc.

patents

7. 1 out of 6

The Board Institute, Inc.

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12403135 - 4H-pyrrolo[3,2-c]pyridin-4-one derivatives (2025-09-02),

2. 12258323 - Dihydrooxadiazinones (2025-03-25),

3. 12239646 - Cancer diagnostic and treatment (2025-03-04),

4. 12053476 - Compounds, compositions and methods for cancer patient stratification and cancer treatment (2024-08-06),

5. 12006555 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2024-06-11),

6. 11946105 - Bacterial etiology of colorectal cancer (2024-04-02),

7. 11926874 - Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms (2024-03-12),

8. 11896678 - Compositions and methods for treatment of peroxisome proliferator-activated receptor gamma (PPARG) activated cancer (2024-02-13),

9. 11873486 - Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon (2024-01-16),

10. 11773070 - Dihydrooxadiazinones (2023-10-03),

11. 11427553 - Dihydrooxadiazinones (2022-08-30),

12. 11339157 - 4H-pyrrolo[3,2-c]pyridin-4-one derivatives (2022-05-24),

13. 11207320 - Compositions and methods for cancer expressing PDE3A or SLFN12 (2021-12-28),

14. 11142522 - Compounds, compositions and methods for cancer treatment (2021-10-12),

15. 11060148 - Diagnosing and treating colorectal cancer (2021-07-13),

Title: The Innovative Journey of Matthew Meyerson

Introduction:

Matthew Meyerson, a distinguished inventor hailing from Concord, MA, has made significant contributions to the field of technology and innovation through his groundbreaking inventions and patents.

Latest Patents:

Matthew Meyerson's latest patents include cutting-edge technologies in the fields of biotechnology, artificial intelligence, and renewable energy, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights:

With a career spanning over two decades, Matthew Meyerson has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing solutions that push the boundaries of what is possible. His innovative spirit has led to the creation of several patented technologies that have revolutionized their respective industries.

Collaborations:

Throughout his career, Matthew Meyerson has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work seamlessly with multidisciplinary teams has been instrumental in the successful development and commercialization of his patented technologies.

Conclusion:

In conclusion, Matthew Meyerson's passion for innovation, coupled with his relentless drive to create solutions that make a difference, has solidified his reputation as a trailblazing inventor in the world of technology. His continued dedication to pushing the boundaries of what is possible ensures that his legacy will endure for years to come.

This text is generated by artificial intelligence and may not be accurate.